Caplin Point's Injectables Unit Aces INVIMA Audit: Latin America Gateway Unlocked

Caplin Point Laboratories Ltd marked a key regulatory milestone as Colombia's INVIMA completed a rigorous inspection of its Puducherry injectables facility. The audit, spanning December 8 to 12, 2025, concluded successfully with zero observations, validating adherence to Good Manufacturing Practices (GMP).​

Key Highlights

Inspection focused on the sterile injectables unit, capable of producing vials, ampoules, lyophilized products, and pre-filled syringes for emerging markets.​

Builds on prior INVIMA nods for the site's Unit-1 (steriles in 2019, softgels in 2024), signaling consistent quality excellence.​

Strengthens Caplin Point's dominance in Latin America and Africa, where it supplies diverse formats like tablets, capsules, and topicals.​

This approval accelerates growth in high-value injectables, aligning with the firm's expansion into regulated Latin American markets amid rising global demand.​

Sources: BSE India, Caplin Point Laboratories Ltd, Money.rediff.com​